Efficacy and Safety of Cannabis Transdermal Patch for Alleviating Psoriasis Symptoms: A Randomized Controlled Trial

Thai Traditional Medical Knowledge Fund0 个研究点目标入组 60 人开始时间: 2022年5月18日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. More than 18 years old
•2. Has been diagnosed with mild to moderate plaque type psoriasis with baseline PASI score less than 10 by a board-certified dermatologist
•3. Have two or more psoriasis plaque of comparable size and severity
•4. Abstain from topical treatment for psoriasis more than 2 weeks prior to the research
•5. Could completely contemplate Thai language
•6. Have ability and willingness to sign inform-consent form for the research

•1. Pregnant women or women who are currently breastfed.
•2. Contraindication to cannabis transdermal patch (Allergy to products of CanPatch or have history of severe cardiovascular disease, liver disease, renal disease and serious psychiatric disease)
•3. Addictive behavior or previously defined as abuse of cannabis (Determined through patient interview and medical records)
•4. Receive biologics therapy for psoriasis treatments
•5. Patients who have had less than 12 weeks of systemic conventional therapy for psoriasis (oral medications or phototherapy)
•6. Patients who have been receiving systemic conventional therapy for psoriasis (oral medications or phototherapy) for more than 12 weeks, but who have seen variations in psoriasis symptoms or adjustments to their medication or phototherapy regimen within the past 12 weeks.

发起方

Thai Traditional Medical Knowledge Fund